Pulmonary actinomycosis complicating infliximab therapy for Crohn's disease

Thorax

Volumn 62, Issue 11, 2007, Pages 1013-1014

  Cohen, Richard D ^a,b   Bowie, W R ^a   Enns, R ^a   Flint, J ^a   Fitzgerald, J M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Gordon and Leslie Diamond Health Care Centre Vancouver Coastal Health   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; CLARITHROMYCIN; DOXYCYCLINE; INFLIXIMAB; MERCAPTOPURINE; PENICILLIN G;

ACTINOMYCOSIS; ADULT; ARTICLE; BRONCHOSCOPY; BRONCHUS BIOPSY; CASE REPORT; CELLULAR IMMUNITY; CONTINUOUS INFUSION; CROHN DISEASE; HUMAN; HUMAN TISSUE; MALE; OXYGEN THERAPY; PLEURA EFFUSION; PRIORITY JOURNAL; THORAX RADIOGRAPHY; TRACHEOBRONCHIAL TOILET; TUBERCULIN TEST;

ACTINOMYCOSIS; ANTIBODIES, MONOCLONAL; CROHN DISEASE; GASTROINTESTINAL AGENTS; HUMANS; LUNG DISEASES; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS;

EID: 36049010417     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.2006.075150     Document Type: Article

References (13)

1. Yildiz O, Doganay M. Actinomycoses and Nocardia pulmonary infections. Curr Opin Pulm Med 2006;12:228-34.
2. Fisher M. "Miliary" actinomycosis. J Can Assoc Radiologists 1980;31:149-50.
3. Ariel A, Breuer R, Kamal N, et al. Endobronchial actinomycosis simulating bronchogenic carcinoma. Chest 1991;99:493-5.
4. Bassiri A, Girgis R, Theodore J. Actinomyces odontolyticus thoracopulmonary infections: two cases in lung and heart-lung transplant recipients and a review of the literature. Chest 1996;109:1109-11.
5. Cendan I, Klapholz A, Talawera W. Pulmonary actinomycosis: a cause of endobronchial disease in a patient with AIDS. Chest 1993;103:1886-7.
6. Charalabopoulos K, Charalabopoulos AK, Papalimneou V, et al. Lung, pleural and colon actinomycosis in an immunocompromised patient: a rare form of presentation. Chemotherapy 2003;49:209-11.
7. Russo T. Agents of actinomycosis. In: Mandell G, Bennett J, Dolin R, eds. Mandell, Douglas and Bennett's principles and practice of infectious diseases, 6th edn. New York: Elsevier/Churchill Livingstone, 2005:2924-31.
8. Blonski W, Lichtenstein GR. Complications of biological therapy for inflammatory bowel diseases. Curr Opin Gastroenterol 2006;22:30-43.
9. Baert F, D'Haens G, Peeters M, et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999;116:22-8.
10. Bell S, Kamm M. The clinical role of anti-TNF alpha antibody treatment in Crohn's disease. Alimentary Pharmacol Ther 2000;14:501-14.
11. Reich K, Nestle F, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005;366:1367-74.
12. Sandborn W, Rachmilewitz D, Hanauer S, et al. Infliximab induction and maintenance therapy for ulcerative colitis: the ACT 2 trial. Gastroenterology 2005;128:A-104.
13. Crum NF, Lederman ER, Wallace MR. Infections associated with tumor necrosis factor-alpha antagonists. Medicine (Baltimore) 2005;84:291-302.